Naslov
First-line empirical H. pylori eradication therapy in Europe: results from 30,000 cases of the European registry on H. pylori management (HP- EUREG)

Autori
O. P. Nyssen , Á. Pérez-Aísa , D. Vaira , L. Jonaitis , B. Tepes , A. Keco-Huerga , M. Castro- Fernández , A. Lucendo , D. Bordin , N. Brglez Jurecic , L. Vologzhanina, M. Caldas1 , G. Fadieienko, R. Abdulkhakov, L. Bujanda, M. Leja, M. Romano, S. Georgopoulos, Ante Tonkić, H. Simsek, A. Gasbarrini, G. M Buzas, P. Phull, M. Venerito, P. Malfertheiner, J. Kupčinskas , G. Babayeva, O. Shvets, F. Lerang, R. Marcos Pinto, T. Rokkas, I. Simsek, S. Smith, Y. Niv, D. Lamarque, F. Heluwaert, A. Goldis, W. Marlicz, V. Milivojevic, L. Boyanova, L. Kunovský, V. Lamy, C. Beglinger, P. Bytzer, L. Capelle, I. Puig, F. Mégraud, C. O’Morain, J. P. Gisbert

Kolaboracija
Hp-EuReg Investigators

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
34th International Workshop on Helicobacter & Microbiota in Inflammation & Cancer / - , 2021, 23-25

Skup
International Workshop on Helicobacter and Microbiota in Inflammation and Cancer

Mjesto i datum
Online, 18.09.2021. - 18.09.2021

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Helicobacter pylori ; eradication therapy

Sažetak
Background: The best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care. Design: International multicentre prospective non- interventional registry starting in 2013 aimed to evaluate the decisions and outcomes in H. pylori management by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap up to February 2021. Variables included: demographics, previous eradication attempts, prescribed treatment, adverse events, and outcomes. Modified intention-to-treat (mITT) and per-protocol (PP) analyses were performed and data were subject to quality review to ensure information reliability. Results: In total 41, 562 patients from 31 European countries were evaluated and 29, 634 (70%) firstline empirical H. pylori treatments were included for analysis. Triple therapy with amoxicillin and clarithromycin was most commonly prescribed (39%), followed by non-bismuth concomitant treatment (18%) and bismuth quadruple (three-in-one single capsule) (12%), achieving 84%, 90% and 94% mITT eradication rate, respectively. Over 90% effectiveness was obtained only with 10 and 14-day bismuth quadruple or with 14-day concomitant treatment (Table). Longer treatment duration, higher acid inhibition and compliance were associated with higher eradication rates. Conclusions: Management of H. pylori infection by European gastroenterologists is heterogeneous. Only quadruple therapies lasting at least ten days are able to achieve approximately 90% eradication rates.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA